Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $42.68 is 42.27% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 43.98||$ 50.05|
|Low:||$ 42.49||$ 30|
ETFs with ARNA as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|2.46%||The Obesity ETF (SLIM)||-3.40 (-9.25%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver clinical utility across therapeutic areas. Our proprietary, internally-developed pipeline includes multiple potentially first- or best-in-class programs. Our three most advanced investigational clinical programs are: ralinepag (APD811), which we are currently preparing for a Phase 3 program for pulmonary arterial hypertension, or PAH; etrasimod (APD334), which is being studied in Phase 2 trials for immune and inflammatory conditions with an initial focus on ulcerative colitis and hepatic conditions; and APD371 for visceral pain conditions and which is being studied in a Phase 2 trial for treatment of pain associated with Crohn's disease, or CD. ... More ...
Nasdaq Official Price
Jan. 17, 2019
Jan. 17, 2019